MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Net Income 2011-2026 | EW
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.07 B | 4.17 B | 1.4 B | 1.52 B | 1.5 B | 823 M | 1.05 B | 722 M | 584 M | 570 M | 495 M | 811 M | 392 M | 293 M | 237 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.17 B | 237 M | 1.04 B |
Quarterly Net Income Edwards Lifesciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 291 M | 333 M | 358 M | - | 3.07 B | 366 M | 352 M | - | 385 M | 307 M | 340 M | - | 344 M | 406 M | 374 M | - | 340 M | 490 M | 338 M | 310 M | 325 M | -122 M | 311 M | 280 M | 275 M | 242 M | 250 M | 7 M | 226 M | 283 M | 207 M | -2.8 M | 170 M | 186 M | 230 M | 158 M | 141 M | 127 M | 143 M | 141 M | 118 M | 113 M | 123 M | 109 M | 94.6 M | 547 M | 60.3 M | 75.1 M | 76.8 M | 93.3 M | 144 M | 91.1 M | 69.2 M | 67.8 M | 65.1 M | 63.1 M | 51.6 M | 58.1 M | 63.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.07 B | -122 M | 256 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 9.13 | -0.76 % | $ 327 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 9.38 | -1.78 % | $ 722 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Inogen
INGN
|
-22.7 M | $ 6.5 | 1.25 % | $ 173 M | USA |
 |
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.35 | 1.89 % | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
22.5 M | $ 98.74 | -2.99 % | $ 1.26 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 16.35 | 0.74 % | $ 384 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
LENSAR
LNSR
|
-31.4 M | $ 5.52 | -1.08 % | $ 63.6 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 36.64 | -1.19 % | $ 1.14 B | USA |
 |
Medtronic PLC
MDT
|
4.66 B | $ 87.67 | -0.24 % | $ 113 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
-3.7 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 24.45 | -0.85 % | $ 207 M | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 11.79 | -1.17 % | $ 467 M |  Curacao |
 |
Outset Medical
OM
|
-81.7 M | $ 3.52 | -0.28 % | $ 53.5 K | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.6 | -10.61 % | $ 32.7 M | USA |
 |
Aethlon Medical
AEMD
|
-13.4 M | $ 2.27 | -2.16 % | $ 3.54 M | USA |
 |
PAVmed
PAVM
|
-64.2 M | $ 8.94 | -3.87 % | $ 64.7 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 63.65 | 0.55 % | $ 3.47 B |  Britain |
 |
InspireMD
NSPR
|
-48.8 M | $ 1.73 | -2.26 % | $ 111 M | Israel |
 |
Insulet Corporation
PODD
|
247 M | $ 218.11 | 0.98 % | $ 15.3 B | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 11.41 | 0.18 % | $ 1.54 B | USA |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 3.9 | -1.52 % | $ 166 M | USA |
 |
Penumbra
PEN
|
178 M | $ 336.42 | 0.04 % | $ 13.1 B | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.94 | -3.9 % | $ 582 M | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-26.9 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.68 | -2.2 % | $ 28.5 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 50.45 | -1.87 % | $ 1.48 B | USA |